Affimed N.V. (AFMD)
| Market Cap | 42.65M |
| Revenue (ttm) | 6.29M |
| Net Income (ttm) | -78.04M |
| Shares Out | 15.68M |
| EPS (ttm) | -5.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,461 |
| Open | 3.030 |
| Previous Close | 3.000 |
| Day's Range | 2.720 - 3.030 |
| 52-Week Range | 2.720 - 8.950 |
| Beta | 2.10 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+488.24%) |
| Earnings Date | Nov 14, 2024 |
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme... [Read more]
Financial Performance
In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AFMD stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 488.24% from the latest price.
News
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations & Director of Investor Relations Shawn Leland...
Affimed Reports Third Quarter 2024 Financial Results & Business Update
MANNHEIM, Germany, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
Affimed to Present at the Cantor Global Healthcare Conference 2024
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Conference Call September 5, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head, Investor Relations Shawn Leland - Chief Executive Officer Andreas ...
Affimed Reports Second Quarter 2024 Financial Results & Business Update
MANNHEIM, Germany, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
On 06/11/24, I published an article on Affimed focused on my belief the company's upcoming acimtamig update would be positive. It was, and Affimed's stock popped the next day. The stock has since drop...
Affimed Appoints Shawn M. Leland as Chief Executive Officer
MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD) Q1 2024 Earnings Conference Call June 12, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head, IR Andreas Harstrick – CMO and Interim CEO Michael Wolf – VP, Fin...
Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) -
Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
Affimed's 06/01/24 update on AFM24 means the company has a second viable commercial asset. This is why the stock popped after ASCO. Acimtamig's update is due before the end of this month. If it is p...
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
MANNHEIM, Germany, June 01, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic...
Affimed Announces Annual General Meeting of Shareholders
MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
MANNHEIM, Germany, May 23, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today ...
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today ...
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
Affimed Reports 2023 Financial Results and Operational Progress
MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Affimed Announces 1-for-10 Reverse Stock Split
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed Announces Leadership Change and Organizational Restructuring
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patients back their innate ...